Lyell Immunopharma, Inc. (LYEL) stock
LYELNasdaqPharmaceutical PreparationsFiscal year ends December 31
$13.67−0.98 (-6.69%)
Close on Nov 17, 2026Market cap $334.99MP/E –Yield –
Lyell Immunopharma operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Lyell Immunopharma's operating cash flow for the twelve months ending Jun 30, 2026 was -$133.26M. For fiscal 2025 it was -$150.02M. The highest annual figure on record is $39.47M in fiscal 2019.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$150.02M | – |
| FY2024 | Dec 31, 2024 | -$162.39M | – |
| FY2023 | Dec 31, 2023 | -$163.69M | – |
| FY2022 | Dec 31, 2022 | -$169.56M | – |
| FY2021 | Dec 31, 2021 | -$126.25M | – |
| FY2020 | Dec 31, 2020 | -$160.87M | -507.5% |
| FY2019 | Dec 31, 2019 | $39.47M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$33.92M | – |
| Q1 FY2026 | Mar 31, 2026 | -$38.51M | – |
| Q4 FY2025 | Dec 31, 2025 | -$32.25M | – |
| Q3 FY2025 | Sep 30, 2025 | -$28.58M | – |
| Q2 FY2025 | Jun 30, 2025 | -$34.46M | – |
| Q1 FY2025 | Mar 31, 2025 | -$54.74M | – |
| Q4 FY2024 | Dec 31, 2024 | -$47.24M | – |
| Q3 FY2024 | Sep 30, 2024 | -$35.04M | – |
| Q2 FY2024 | Jun 30, 2024 | -$38.09M | – |
| Q1 FY2024 | Mar 31, 2024 | -$42.02M | – |
| Q4 FY2023 | Dec 31, 2023 | -$40.64M | – |
| Q3 FY2023 | Sep 30, 2023 | -$37.69M | – |
| Q2 FY2023 | Jun 30, 2023 | -$39.16M | – |
| Q1 FY2023 | Mar 31, 2023 | -$46.21M | – |
| Q4 FY2022 | Dec 31, 2022 | -$40.27M | – |
| Q3 FY2022 | Sep 30, 2022 | -$37.10M | – |
| Q2 FY2022 | Jun 30, 2022 | -$44.33M | – |
| Q1 FY2022 | Mar 31, 2022 | -$47.85M | – |
| Q4 FY2021 | Dec 31, 2021 | -$33.21M | – |
| Q3 FY2021 | Sep 30, 2021 | -$25.49M | – |
| Q2 FY2021 | Jun 30, 2021 | -$33.95M | – |
| Q1 FY2021 | Mar 31, 2021 | -$33.60M | – |
| Q4 FY2020 | Dec 31, 2020 | -$26.73M | – |
| Q3 FY2020 | Sep 30, 2020 | -$21.63M | – |
See a number that looks wrong?